Prostate Cancer Clinical Trial
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
Safety and tolerability profile of ODM-208 will be explored
Main Inclusion Criteria:
Written informed consent (IC) obtained.
Male aged ≥ 18 years.
Histologically confirmed adenocarcinoma of the prostate.
Castration resistant prostate cancer with serum testosterone < 50 ng/dl.
Ongoing androgen deprivation therapy with GnRH analogue or antagonist, or have had bilateral orchiectomy.
Received at least one prior line of novel hormonal androgen receptor (AR) targeted therapy (e.g. abiraterone, enzalutamide).
ECOG performance status 0-1.
Adequate marrow, liver and kidney function.
Able to swallow study treatment.
Part 1: Treatment with at least 1 line of chemotherapy or ineligibility for chemotherapy. Part 2: Treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (CSPC) or in CRPC.
Part 2: Identified activating mutation in the LBD of AR in plasma ctDNA confirmed by the central testing.
Main Exclusion Criteria:
History of pituitary or adrenal dysfunction.
Known brain metastases or active leptomeningeal disease.
Active infection or other medical condition that would make corticosteroid contraindicated.
Poorly controlled diabetes.
Hypotension or uncontrolled hypertension.
Clinically significantly abnormal serum potassium or sodium level.
Active or unstable cardio/cerebro-vascular disease including thromboembolic events.
Prolonged QTcF interval.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Baltimore Maryland, 21201, United States
Omaha Nebraska, 68114, United States
Buffalo New York, 14203, United States
Helsinki , , Finland
Tampere , , Finland
Bordeaux , , France
Lyon , , France
Marseille , , France
Strasbourg , , France
Suresnes , 92150, France
Villejuif , , France
Bedlington , , United Kingdom
Cardiff , CF14 , United Kingdom
Glasgow , G12 0, United Kingdom
Liverpool , , United Kingdom
London , SW3 6, United Kingdom
London , , United Kingdom
Manchester , , United Kingdom
Preston , PR2 9, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.